E. Bortey

A. Sanyal, E. Bortey, W. Forbes, 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

A comparison of cilostazol and pentoxifylline for treating intermittent claudication.

D. Dawson, D. Strandness, D. Strandness, 2000, The American journal of medicine.

Once-daily Mesalamine Formulation for Maintenance of Remission in Ulcerative Colitis: A Randomized, Placebo-controlled Clinical Trial

C. Paterson, E. Bortey, W. Forbes, 2015, Journal of clinical gastroenterology.

Clinical trial: once‐daily mesalamine granules for maintenance of remission of ulcerative colitis – a 6‐month placebo‐controlled trial

E. Bortey, W. Forbes, G. Lichtenstein, 2010, Alimentary pharmacology & therapeutics.

P176 Patient reported outcome measures derived from the Crohn's Disease Activity Index: Correlation between PRO2 and PRO3 scores and CDAI-defined clinical thresholds

M. Vandervoort, G. D'Haens, W. Sandborn, 2014 .

Prevention of travelers' diarrhea with rifaximin in US travelers to Mexico.

H. Dupont, E. Bortey, W. Forbes, 2010, Journal of travel medicine.

Rapid identification of motile Aeromonas.

F. Meier, E. Bortey, H. Dalton, 1992, Diagnostic microbiology and infectious disease.

Rifaximin therapy for patients with irritable bowel syndrome without constipation.

W. Chey, A. Lembo, M. Pimentel, 2011, The New England journal of medicine.

Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis

J. Bajaj, C. Paterson, E. Bortey, 2014, Alimentary pharmacology & therapeutics.

Development and Validation of a Biomarker for Diarrhea-Predominant Irritable Bowel Syndrome in Human Subjects

G. Barlow, A. Lembo, M. Pimentel, 2015, PloS one.

Rifaximin treatment in hepatic encephalopathy.

C. Leevy, A. Sanyal, E. Bortey, 2010, The New England journal of medicine.

T1390 Rifaximin for the Treatment of Diarrhea-Associated Irritable Bowel Syndrome: Short Term Treatment Leading to Long Term Sustained Response

A. Lembo, M. Pimentel, Y. Ringel, 2008 .

Safety, Efficacy, and Pharmacokinetics of Balsalazide in Pediatric Patients With Mild-to-Moderate Active Ulcerative Colitis: Results of a Randomized, Double-blind Study

H. Pieniaszek, T. Attard, M. Heyman, 2009, Journal of pediatric gastroenterology and nutrition.

Rifaximin Significantly Improves Quality of Life Versus Placebo in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: 1182

W. Chey, N. Talley, A. Lembo, 2008 .

Once-Daily 1.5-G Granulated mesalamine Is Effective and Safe in Maintenance of Remission in Mild-to-Moderate Ulcerative Colitis: 1128

E. Bortey, W. Forbes, R. Pruitt, 2008 .

Once-Daily 1.5-G Granulated mesalamine Effectively Maintains Remission in Patients with Ulcerative Colitis Who Switch from Different 5-ASA Formulations: 1100

E. Bortey, W. Forbes, G. Lichtenstein, 2008 .

Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double‐blind, placebo‐controlled trials

W. Chey, L. Chang, P. Schoenfeld, 2014, Alimentary pharmacology & therapeutics.

Tu1390 Improvement in Quality of Life of Patients With Irritable Bowel Syndrome With Diarrhea is Sustained for 10 Weeks Following a 2-Week Course of Rifaximin

A. Lembo, M. Pimentel, Lin Chang, 2012 .

The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693.

D. Hilt, J. Gerven, E. Bortey, 2005, British journal of clinical pharmacology.

A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial.

D. Dawson, D. Strandness, D. Strandness, 1999, Archives of internal medicine.

195 RIFAXIMIN DECREASES VENOUS AMMONIA CONCENTRATIONS AND TIME-WEIGHTED AVERAGE AMMONIA CONCENTRATIONS CORRELATE WITH OVERT HEPATIC ENCEPHALOPATHY (HE) AS ASSESSED BY CONN SCORE IN A 6-MONTH STUDY

A. Sanyal, E. Bortey, W. Forbes, 2010 .

15 RIFAXIMIN TREATMENT IMPROVED QUALITY OF LIFE IN PATIENTS WITH HEPATIC ENCEPHALOPATHY: RESULTS OF A LARGE, RANDOMIZED, PLACEBO-CONTROLLED TRIAL

A. Sanyal, E. Bortey, W. Forbes, 2010 .

109 LONG TERM EFFICACY AND SURVIVAL IN PATIENTS TREATED WITH THE GUT-SELECTIVE ANTIBIOTIC RIFAXIMIN (550 MG BID) FOR THE MAINTENANCE OF REMISSION FROM OVERT HEPATIC ENCEPHALOPATHY

J. Talwalkar, E. Bortey, W. Forbes, 2011 .

645 RATES OF COMMONLY OCCURING INFECTIONS IN CIRRHOSIS PATIENTS REMAIN STABLE DURING LONG-TERM RIFAXIMIN TREATMENT

A. Sanyal, E. Bortey, W. Forbes, 2012 .

Analysis of opioid-mediated analgesia in Phase III studies of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain

L. Webster, C. Paterson, E. Bortey, 2015, Journal of pain research.

Testing for consistency in a single multicenter trial.

V. Chinchilli, E. Bortey, 1991, Journal of biopharmaceutical statistics.

Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication.

J. Crouse, D. Hunninghake, M. Elam, 1998, Arteriosclerosis, thrombosis, and vascular biology.

Mesalazine granules 1.5 g once‐daily maintain remission in patients with ulcerative colitis who switch from other 5‐ASA formulations: a pooled analysis from two randomised controlled trials

E. Bortey, W. Forbes, G. Lichtenstein, 2012, Alimentary Pharmacology and Therapeutics.

Objectives of Biomarkers in Early Drug Development Biomarkers for Pharmacological Effects Biomarkers for (patho)physiological Principle Biomarkers for Therapeutic Principle Table 1 Number of Tests within Individual Domains Neuropsychological Domains Neuroleptics Selective Serotonin Re-uptake Inhibit

M. Ferrari, F. Zitman, D. Hilt, 2022 .

An interim analysis of a phase 2 trial evaluating oral nalbuphine extended release for treating chronic cough in idiopathic pulmonary fibrosis

T. Maher, E. Bortey, W. Forbes, 2022, 12.01 - Idiopathic interstitial pneumonias.

O-002 Evaluation of the Operating Properties of Candidate Patient Reported Outcomes for Use in Randomized Controlled Trials in Crohn’s Disease

M. Vandervoort, G. D'Haens, W. Sandborn, 2013 .

Applying survival methodology to adverse experience occurrences in controlled clinical trials.

A. Gould, E. Bortey, 1991, Journal of biopharmaceutical statistics.

943a Oral Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Noncancer Pain

E. Bortey, W. Forbes, J. Peppin, 2012 .

S446 Results from KRYPTOS, a Phase 2/3 Study of Lirentelimab (AK002) in Adults and Adolescents With EoE

I. Hirano, D. Leiman, R. Genta, 2022, American Journal of Gastroenterology.

475i Rifaximin Treatment for 2 Weeks Provides Acute and Sustained Relief Over 12 Weeks of IBS Symptoms in Non-Constipated Irritable Bowel Syndrome: Results From 2 North American Phase 3 Trials (Target 1 and Target 2)

W. Chey, A. Lembo, M. Pimentel, 2010 .

Nalbuphine Tablets for Cough in Patients with Idiopathic Pulmonary Fibrosis

T. Maher, E. Bortey, S. Hart, 2023, NEJM Evidence.

Rifaximin therapy for patients with irritable bowel syndrome without constipation.

W. Chey, A. Lembo, M. Pimentel, 2011, The New England journal of medicine.

Mo1116 The Efficacy and Safety of Rifaximin vs. Vancomycin in the Treatment of Mild to Moderate C. difficile Infection: A Randomized Double-Blind Active Comparator Trial

H. Dupont, D. Pardi, E. Bortey, 2012 .

A New Pharmacological Treatment for Intermittent Claudication

D. Dawson, E. Bortey, W. Forbes, 2017 .

Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis.

D. Clemmons, W. Sandborn, C. Paterson, 2015, Gastroenterology.